Depo-Provera Brain Tumor Lawsuits: What’s Happening Right Now and What It Means If You’ve Used the Shot
Last updated: May 16, 2026
The Depo-Provera mass tort litigation is building toward what legal observers are calling its most consequential stretch yet. New lawsuits continued to be filed this week — including cases alleging that long-term use of the injectable birth control caused intracranial meningiomas that led to permanent hearing loss, vision loss, and cognitive damage — while attorneys handling the multi-district litigation are pushing toward the first trials in what is shaping up to be a landmark year for Pfizer’s legal exposure.
Here’s a clear-eyed breakdown of where the litigation stands, what the science says, and what women who’ve used Depo-Provera need to understand about their options right now.
What Is Depo-Provera and What Are the Allegations?
Depo-Provera is an injectable form of birth control containing medroxyprogesterone acetate, a synthetic progestin. Administered by injection every three months, it has been used by millions of women in the United States since the FDA approved it in 1992. Pfizer, through its subsidiary Upjohn, manufactures and markets the drug.
The core allegation across the litigation is straightforward: long-term use of Depo-Provera significantly increases the risk of developing an intracranial meningioma — a tumor that grows along the membranes covering the brain and spinal cord. While meningiomas are often classified as “benign” because they rarely spread, that label is misleading when applied to the brain. A tumor pressing against the brain can cause severe and permanent damage: chronic headaches, vision loss, hearing loss, seizures, cognitive impairment, and, in serious cases, death. Treatment typically requires brain surgery, stereotactic radiosurgery, or prolonged radiation therapy — procedures that carry their own serious risks.
Plaintiffs allege that Pfizer knew or should have known about this risk based on scientific data available for years, and that the company failed to warn patients and prescribing physicians in the United States — even after French regulators and researchers published findings that prompted France to significantly restrict Depo-Provera’s use. A major French pharmacovigilance study found that women who used injectable progestins like Depo-Provera for longer periods faced a meaningfully elevated meningioma risk compared to the general population, a signal that plaintiffs argue should have triggered updated warnings in the U.S. long before it did.
Where the MDL Stands in May 2026
The federal cases have been consolidated into MDL No. 3140 — In Re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation — centralized before U.S. District Judge M. Casey Rodgers in the Northern District of Florida.
The MDL has grown steadily since consolidation, with thousands of cases now pending from women across the country who were diagnosed with intracranial meningiomas following extended Depo-Provera use. The case management process is working through Plaintiff Fact Sheets, defendant discovery, and expert witness designation — the procedural scaffolding that has to be completed before bellwether trials can be scheduled.
Legal observers tracking the docket have flagged 2026 as the year the litigation transitions from intake-and-build mode to active litigation mode. Bellwether trials — the initial test cases that give both sides a realistic read on how juries will respond to the evidence — are expected to be designated and potentially tried this year. Those first verdicts will shape settlement conversations across the entire MDL.
This week’s news coverage of a new case alleging that Depo-Provera-caused meningioma led to permanent hearing loss and vision loss in a plaintiff reflects the ongoing acceleration of filings and the increasingly specific human stories coming out of the litigation. These are not abstract injury claims. The damages being alleged — brain surgery, radiation, loss of major sensory functions at working age — are the kind that move juries and, more practically, motivate corporate defendants to evaluate whether settlement makes more sense than trying individual cases.
Who May Qualify to File a Depo-Provera Lawsuit
Not every woman who has used Depo-Provera has a viable claim, and no attorney worth working with will tell you otherwise. The profile that matches current eligibility criteria in the MDL generally looks like this:
Extended use period. Most attorneys are screening for women who used Depo-Provera for at least one year, with stronger cases typically involving five or more years of consecutive use. The longer the exposure, the stronger the general causation argument based on current science.
Meningioma diagnosis. A diagnosis of intracranial meningioma — confirmed by MRI, CT scan, pathology report, or similar imaging — is the core medical requirement. The tumor must be intracranial (inside the skull) to fall within the current litigation framework. Spinal meningiomas are a separate question.
Timing relative to use. Causation arguments are strongest when the meningioma was diagnosed during or after the period of Depo-Provera use, not decades before or without any documented exposure history. A prescription records review is typically part of the early case evaluation.
No superseding progestin use. Some women’s medical history includes other progestin-based medications (including some treatments for endometriosis, HRT regimens, or other hormonal therapies). Attorneys will review the full medication history because defense counsel will argue that other progestin sources could be the causative factor.
If you match the general profile above — extended Depo-Provera use, followed by or concurrent with a meningioma diagnosis — the window to evaluate your case is right now. The statute of limitations in mass tort cases is one of the most misunderstood concepts in personal injury law: many women assume they have more time than they do, particularly when they don’t connect their diagnosis to their prior birth control use. In most states, the clock on a pharmaceutical product liability claim runs from the date you knew or reasonably should have known about the connection — and “reasonably should have known” is a legal standard that courts apply with less flexibility than most people expect.
What Damages Could Be on the Table
Depo-Provera meningioma cases are serious personal injury claims, and the damages available reflect the severity of the injury category:
Medical expenses. Brain surgery, radiosurgery, radiation therapy, neurology follow-up, medication, and any rehabilitation costs. In cases involving complex surgical interventions, these costs run well into six figures and sometimes beyond.
Lost wages and earning capacity. Meningioma surgeries and treatment carry real recovery timelines. For women who lost employment or whose career trajectory was disrupted, that economic impact is a documented, compensable element of the claim.
Pain and suffering. The non-economic damages — the experience of living with a brain tumor diagnosis, undergoing brain surgery, recovering from radiation, and managing permanent neurological changes — form a significant component of these claims.
Permanent impairment. Cases involving permanent vision loss, hearing loss, or cognitive deficits carry higher damage valuations because the impact is lifelong, not just during recovery. How courts will calculate and present these losses will be clarified as the first bellwether verdicts emerge.
It’s too early to cite reliable settlement ranges for the Depo-Provera MDL — the litigation is still building toward its first trials, and without bellwether verdicts, any number circulating online should be treated as speculation. What attorneys can evaluate today is whether your specific case facts, medical records, and usage history position you for inclusion in the litigation. That evaluation is free and confidential.
What to Do If You Think You Have a Claim
If you used Depo-Provera for an extended period and have been diagnosed with an intracranial meningioma, the smartest first step is a case evaluation with an attorney who is currently handling Depo-Provera MDL cases. Not a general personal injury attorney who handles these on the side — one who is actively working in the MDL, knows the docket, has submitted Plaintiff Fact Sheets, and can tell you where your case fits in the current litigation timeline.
Gather what you can before that conversation: prescription records showing Depo-Provera use (your OB/GYN or GP should have these), imaging results or pathology reports showing the meningioma diagnosis, a timeline of when symptoms started, and records of any treatment (surgery, radiation, medication). You won’t need to have everything perfectly organized before a free consultation — attorneys evaluating these cases do records retrieval as part of their intake process — but having a basic picture ready speeds the process.
Legal Giant connects women with personal injury attorneys who are actively working on Depo-Provera claims. Consultations are free, there’s no obligation, and attorneys in this litigation work on contingency — meaning no upfront costs and no fee unless there’s a recovery.
For broader context on how mass tort and product liability cases work — including what the MDL process means for individual claimants — our guide on how long a personal injury lawsuit typically takes is a helpful reference. Cases inside an MDL follow a different timeline than standalone claims, but the general framework for understanding discovery, bellwether trials, and settlement negotiations is the same.
If you have questions about how damages are calculated in a serious injury case like this, our overview of how pain and suffering damages work covers the methodology that applies across personal injury cases, including pharmaceutical claims.
Get a free Depo-Provera case evaluation through Legal Giant.
